WuXi and Lees Pharm collaboration

WuXi to Be Exclusive Supplier of Laboratory Testing Services to Lee’s Pharm

We are delighted to announce that WuXi’s Laboratory Testing Division (LTD) will become the exclusive supplier of the broad range of testing services for the drug discovery and development portfolio of...

Congratulations to Hua Medicine on Filing IND in US for its Novel GKA-based Diabetes...

We are pleased to share with you that our partner, Hua Medicine, has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its novel 4th-Generation glucokinase activator...

WuXiPRA Appoints Two Key Executives

We are pleased to share with you that WuXiPRA, a joint venture we formed together with PRA, has appointed Liedong Xu as its Executive Vice President and Chief Operations Officer and...

WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

We are thrilled to share with you that we have been awarded the 2015 Frost & Sullivan Asian CRO Company of the Year Award.  The award is part of the Frost...

WuXi Healthcare Ventures II Closes with Oversubscription

We are pleased to announce that our WuXi Healthcare Ventures (WXHV) has closed a new fund of $290 million WuXi Healthcare Ventures II, L.P., exceeding the initial target of $200 million. ...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Game Changer: Scientist Mark Waller Ready to “Go” to Next level...

By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx)   Renowned chemist and computational scientist Mark Waller is ready to go to the next...